The reduction in HbA1c is greater in patients starting basal insulin or insulin glargine compared to DPP-4-inhibitors. This was concluded in a study recently published in Nederlands Tijdschrift voor Diabetologie using linked data from out-patient pharmacies and clinical laboratories from the PHARMO Database Network. A sensitivity analysis was performed on patients matched on baseline HbA1c and gender. When matching, only insulin glargine had a greater reduction in HbA1c. Improved glycemic control will lead to fewer hospitalisations, reduced healthcare costs and improved quality of life.

To read more, please click here.

Share this article